Product Details

Introduction

Abeclib 200 mg (Abemaciclib) represents a breakthrough in targeted breast cancer treatment, specifically designed for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. This powerful CDK4/6 inhibitor, manufactured by the renowned Eskayef Pharmaceuticals Ltd. and supplied by Makkaa Pharma, offers new hope for patients at various stages of breast cancer treatment.

What is Abeclib (Abemaciclib)?

Abeclib contains Abemaciclib, a selective CDK4/6 inhibitor that targets specific cellular mechanisms responsible for cancer cell growth. By blocking the activity of cyclin-dependent kinases 4 and 6, Abeclib prevents the phosphorylation of retinoblastoma protein, halting cell cycle progression from G1 to S phase. This targeted approach leads to cancer cell senescence and apoptosis, effectively slowing tumor growth while minimizing impact on healthy cells.

Therapeutic Applications

Abeclib is FDA-approved for multiple breast cancer treatment scenarios:

1. Adjuvant Treatment: Used with endocrine therapy (tamoxifen or aromatase inhibitors) for HR+/HER2-, node-positive early breast cancer patients with high recurrence risk and Ki-67 score ≥20%.
2. First-Line Treatment: Prescribed with aromatase inhibitors as initial endocrine-based therapy for postmenopausal women and men with HR+/HER2- advanced or metastatic breast cancer.
3. Second-Line Treatment: Combined with fulvestrant for adult patients with HR+/HER2- advanced or metastatic breast cancer that has progressed following endocrine therapy.
4. Monotherapy Option: Available as a single-agent treatment for HR+/HER2- advanced or metastatic breast cancer patients whose disease has progressed despite endocrine therapy and prior chemotherapy.

Dosage Guidelines

Abeclib tablets can be taken with or without food, typically following these dosage protocols:

• Combination Therapy: 150 mg twice daily when used with fulvestrant, tamoxifen, or aromatase inhibitors
• Monotherapy: 200 mg twice daily
• Personalized Adjustments: Dosing interruptions or reductions may be recommended based on individual tolerability and side effect management

Quality Assurance

Each Abeclib 200 mg tablet is manufactured under stringent quality control standards by Eskayef Pharmaceuticals Ltd., a leading pharmaceutical company with over 30 years of experience in producing world-class medications. The manufacturing process adheres to international standards, ensuring consistent potency and purity in every dose.

Important Safety Information

Patients should be aware of potential side effects including:

• Diarrhea (may be severe and require antidiarrheal treatment)
• Neutropenia (regular blood count monitoring recommended)
• Interstitial lung disease/pneumonitis (rare but serious)
• Liver function abnormalities
• Venous thromboembolism
• Fatigue, nausea, abdominal pain, and decreased appetite

Drug Interactions

• Strong/Moderate CYP3A Inhibitors: Avoid ketoconazole; dose reduction required with other strong/moderate CYP3A inhibitors
• Strong/Moderate CYP3A Inducers: Concomitant use should be avoided

Special Populations

• Pregnancy: Can cause fetal harm; effective contraception recommended during treatment and for 3 weeks after
• Hepatic/Renal Impairment: No dosage adjustments needed for mild/moderate impairment
• Geriatric Use: No significant differences in safety/effectiveness observed

Global Availability

Makkaa Pharma, your trusted anti-cancer and oncology medicine supplier since 2019, provides worldwide delivery of Abeclib 200 mg tablets within 3-7 working days. Our commitment to quality, compassion, integrity, innovation, and collaboration ensures that patients worldwide receive this life-saving medication promptly when needed.

Storage Recommendations

For optimal potency, store Abeclib 200 mg tablets below 30°C, protected from light and moisture. Always keep out of reach of children.

Why Choose Abeclib from Makkaa Pharma?

1. Guaranteed Quality: Sourced directly from Eskayef Pharmaceuticals Ltd., ensuring authentic, high-quality medication
2. Fast Global Delivery: Receive your treatment within 3-7 working days, anywhere in the world
3. Expert Support: Our knowledgeable team provides guidance on medication information and ordering process
4. Trusted Source: Makkaa Pharma specializes in oncology medications, making us a reliable partner in your cancer treatment journey

For cancer patients seeking advanced treatment options, Abeclib 200 mg represents a significant advancement in targeted therapy with proven efficacy across multiple clinical scenarios. Contact Makkaa Pharma today to learn more about how Abeclib can be integrated into your treatment plan.